Product Name:4-Amino-2,6-dichlorophenol

IUPAC Name:4-amino-2,6-dichlorophenol

CAS:5930-28-9
Molecular Formula:C6H5Cl2NO
Purity:95%+
Catalog Number:CM117324
Molecular Weight:178.01

Packing Unit Available Stock Price($) Quantity
CM117324-500g in stock ȐŞ
CM117324-1000g in stock ȯƃƃ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:5930-28-9
Molecular Formula:C6H5Cl2NO
Melting Point:-
Smiles Code:OC1=C(Cl)C=C(N)C=C1Cl
Density:
Catalog Number:CM117324
Molecular Weight:178.01
Boiling Point:
MDL No:MFCD00007875
Storage:

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Resmetirom
Sept. 13, 2023, Madrigal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for resmetirom for the treatment of adult patients with NASH with liver fibrosis. 
Nonalcoholic steatohepatitis (NASH) is a more advanced form of nonalcoholic fatty liver disease (NAFLD). 
Resmetirom is designed to target the underlying causes of NASH by reducing or eliminating liver fat (steatosis) as well as reducing liver inflammation, liver cell ballooning (hepatocyte cell death), and liver fibrosis that can lead to cirrhosis. Resmetirom is the only orally administered, small-molecule, liver-directed, truly β-selective THR agonist in Phase 3 development.